Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Leukodystrophy as a feature of PIGT-CDG

    Research output: Contribution to journalLetterResearchpeer-review

  4. Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Letter to the Editor. Copenhagen grading of meningioma

    Research output: Contribution to journalLetterResearchpeer-review

  4. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Fluorescein-guided resection of cerebral metastases is associated with greater tumor resection

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The advent of checkpoint immunotherapy, particularly with programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, has provided ground-breaking results in several advanced cancers. Substantial efforts are being made to extend these promising therapies to other refractory cancers such as gliomas, especially glioblastoma, which represents the most frequent and malignant glioma and carries an exceptionally grim prognosis. Thus, there is a need for new therapeutic strategies with related biomarkers. Gliomas have a profoundly immunosuppressive tumour micro-environment and evade immunological destruction by several mechanisms, one being the expression of inhibitory immune checkpoint molecules such as PD-L1. PD-L1 is recognised as an important therapeutic target and its expression has been shown to hold prognostic value in different cancers. Several clinical trials have been launched and some already completed, but PD-1/PD-L1 inhibitors have yet to show convincing clinical efficacy in gliomas. Part of the explanation may reside in the vast molecular heterogeneity of gliomas and a complex interplay within the tumour micro-environment. In parallel, critical knowledge about PD-L1 expression is beginning to accumulate including knowledge on expression levels, testing methodology, co-expression with other checkpoint molecules and prognostic and predictive value. This article reviews these aspects and points out areas where biomarker research is needed to develop more successful checkpoint-related therapeutic strategies in gliomas.

Original languageEnglish
Article numbere12767
JournalNeuropathology and Applied Neurobiology
Volume48
Issue number1
Pages (from-to)e12767
ISSN0305-1846
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

© 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

    Research areas

  • biomarker, checkpoint inhibition, glioblastoma multiforme, glioma, immunotherapy, PD-L1, prognosis, programmed death-ligand 1

ID: 71673679